An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT SOLO)

Roche

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Biological: Tocilizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT01474291

ML27873

Details and patient eligibility

About

This prospective, multi-center, observational study will evaluate factors influencing the use of tocilizumab (RoActemra/Actemra) as monotherapy in rheumatoid arthritis patients in real life setting. Data will be collected from participants for 12 months following initiation of tocilizumab treatment.

Enrollment: 608 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult participants, >/= 18 years of age
• Patients with rheumatoid arthritis for whom the rheumatologist decides to start tocilizumab in combination with DMARD or as monotherapy

Exclusion criteria

• Current participation in a clinical trial in rheumatoid arthritis

Trial design

608 participants in 1 patient group

Tocilizumab

Description:

Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.

Treatment:

Biological: Tocilizumab